Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study

Journal of Hypertension

Volumn 28, Issue 10, 2010, Pages 2076-2083

  Irvin, Marguerite R ^a   Lynch, Amy I ^b   Kabagambe, Edmond K ^a   Tiwari, Hemant K ^a   Barzilay, Joshua I ^c,d   Eckfeldt, John H ^b   Boerwinkle, Eric ^e   Davis, Barry R ^e   Ford, Charles E ^e   Arnett, Donna K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c KAISER PERMANENTE   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

amlodipine; angiotensin converting enzyme; chlorthalidone; hypertension treatment; lisinopril; reninangiotensinaldosterone system; SCNN1A; thiazide diuretics

Indexed keywords

AMLODIPINE; ATENOLOL; CHLORTALIDONE; CLONIDINE; EPITHELIAL SODIUM CHANNEL; GLUCOSE; HYDRALAZINE; LISINOPRIL; RESERPINE;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

EID: 77957281447     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833c7a4d     Document Type: Article

References (49)

1. Jackson JH, Sobolski J, Krienke R, Wong KS, Frech-Tamas F, Nightengale B. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines. J Am Board Fam Med 2008; 21:512521.
2. Wright JT Jr, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832-842.
3. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166:2191-2201.
4. Messerli FH, Grossman E, Goldbourt U. Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens 2001; 14:12S-16S.
5. Whaley-Connell A, Sowers JR. Hypertension management in type 2 diabetes mellitus: recommendations of the Joint National Committee VII. Endocrinol Metab Clin North Am 2005; 34:63-75.
6. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703-713.
7. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207.
8. Muscogiuri G, Chavez AO, Gastaldelli A, Perego L, Tripathy D, Saad MJ, et al. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol 2008; 6:301-312.
9. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22:2253-2261.
10. Gorden P. Glucose intolerance with hypokalemia. Failure of short-term potassium depletion in normal subjects to reproduce the glucose and insulin abnormalities of clinical hypokalemia. Diabetes 1973; 22:544-551.
11. Rowe JW, Tobin JD, Rosa RM, Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 1980; 29:498502.
12. Bozkurt O, de Boer A, Grobbee DE, de Leeuw PW, Kroon AA, Schiffers P, et al. Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens 2009; 22:545-551.
13. Liamis G, Milionis H, Elisaf M. Blood pressure drug therapy and electrolyte disturbances. Int J Clin Pract 2008; 62:1572-1580.
14. Shafi T, Appel LJ, Miller ER III, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008; 52:1022-1029.
15. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J 2002; 2:309-317.
16. ACR Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283:1967-1975.
17. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9:342-360.
18. Grimm RH Jr, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, et al. Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2001; 37:19-27. (Pubitemid 32064234)
19. ACR Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. Hypertension 2003; 42:239-246.
20. Report of the Special Emphasis Panel on Opportunities and Obstacles to Genetic Research in NHLBI Clinical Studies. Bethesda, MD: National Heart, Lung, and Blood Institute, NIH; 1997. 2009.
21. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 1999; 9:936-949.
22. Kim DS, Choi SI, Lee HS, Park JK, Yi HK. Determination of human angiotensin converting enzyme (ACE) gene polymorphisms in erectile dysfunction: frequency differences of ACE gene polymorphisms according to the method of analysis. Clin Chem Lab Med 2001; 39:11-14.
23. Baroudi T, Bouhaha R, Moran-Moguel C, Sanchez-Corona J, Ben Maiz H, Kammoun AH, et al. Association of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene with type 2 diabetes in two ethnic groups of Jerba Island in Tunisia. J Renin Angiotensin Aldosterone Syst 2009; 10:35-40.
24. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, et al. The D allele of the angiotensin-converting enzyme insertion/deletion (I/D) polymorphism is a risk factor for type 2 diabetes in a population-based Japanese sample. Endocr J 2003; 50:393-398.
25. Feng Y, Niu T, Xu X, Chen C, Li Q, Qian R, et al. Insertion/deletion polymorphism of the ACE gene is associated with type 2 diabetes. Diabetes 2002; 51:1986-1988.
26. Yang M, Qiu CC, Xu Q, Xiang HD. Association of angiotensin converting enzyme gene I/D polymorphism with type 2 diabetes mellitus. Biomed Environ Sci 2006; 19:323-327.
27. Cheverud JM. A simple correction for multiple comparisons in interval mapping genome scans. Heredity 2001; 87:52-58.
28. Ramachandran V, Ismail P, Stanslas J, Shamsudin N, Moin S, Mohd JR. Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential hypertension and type 2 diabetes mellitus in Malaysian subjects. J Renin Angiotensin Aldosterone Syst 2008; 9:208214.
29. Ryan AS, Nicklas BJ, Berman DM, Ferrell RE. The insertion/deletion polymorphism of the ACE gene is related to insulin sensitivity in overweight women. Diabetes Care 2001; 24:1646-1652.
30. Thomas GN, Tomlinson B, Chan JC, Sanderson JE, Cockram CS, Critchley JA. Renin-angiotensin system gene polymorphisms, blood pressure, dyslipidemia, and diabetes in Hong Kong Chinese: a significant association of tne ACE insertion/deletion polymorphism with type 2 diabetes. Diabetes Care 2001; 24:356-361.
31. van Valkengoed IG, Stronks K, Hahntow IN, Hoekstra JB, Holleman F. The angiotensin converting enzyme insertion/deletion polymorphism and differences in fasting plasma glucose in Hindustani Surinamese, African Surinamese and ethnic Dutch: the population-based SUNSET-study. Diabetes Res Clin Pract 2008; 81:e12-e14.
32. Bonnet F, Patel S, Laville M, Balkau B, Favuzzi A, Monti LD, et al. Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. Diabetes Care 2008; 31:789-794.
33. Ohishi M, Rakugi H, MikiT, KatsuyaT, OkamuraA, Kamide K, et al. Deletion polymorphism of angiotensin-converting enzyme gene is associated with postprandial hyperglycaemia in individuals undergoing general check-up. Clin Exp Pharmacol Physiol 2000; 27:483-487.
34. Perticone F, Ceravolo R, Iacopino S, Cloro C, Ventura G, Maio R, et al. Relationship between angiotensin-converting enzyme gene polymorphism and insulin resistance in never-treated hypertensive patients. J Clin Endocrinol Metab 2001; 86:172-178.
35. Akin F, Turgut S, Dursunoglu D, Turgut G, Karasu U, Gur S. ACE gene polymorphism and cardiac structure in patients with insulin resistance. Mol Biol Rep 2009; 36:623-629.
36. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.
37. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92:13871388.
38. Zhu X, Bouzekri N, Southam L, Cooper RS, Adeyemo A, McKenzie CA, et al. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet 2001; 68:1139-1148.
39. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996; 58:12681278.
40. Keavney B, McKenzie CA, Connell JM, Julier C, Ratcliffe PJ, Sobel E, et al. Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet 1998; 7:1745-1751.
41. KimTH, Chang HS, ParkSM, Nam BY, ParkJS, RhimT, et al. Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clin Exp Allergy 2008; 38:1727-1737.
42. Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994; 367:463-467.
43. Conde L, Vaquerizas JM, Dopazo H, Arbiza L, Reumers J, Rousseau F, et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res 2006; 34:W621-W625.
44. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large-scale variation in the human genome. Nat Genet 2004; 36:949-951.
45. ACR Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2002; 288:2981-2997.
46. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat Med 2005; 24:2911-2935.
47. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009. [Epub ahead of print]
48. Dolley G, Lamarche B, Despres JP, Bouchard C, Perusse L, Vohl MC. Phosphoinositide cycle gene polymorphisms affect the plasma lipid profile in the Quebec Family Study. Mol Genet Metab 2009; 97:149-154.
49. Gilon P, Henquin JC. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr Rev 2001; 22:565-604.